Harvard Bioscience Inc.

Biotech firm Harvard Apparatus Regenerative Technology of Holliston has closed a previously announced public stock offering after raising about $8.6 million, the company announced this week.

Harvard Bioscience Inc. said a weaker U.S. dollar compared to the British pound helped bump its third quarter revenues slightly.

Harvard Bioscience Inc. (NASDAQ:HBIO), a Holliston-based manufacturer of life sciences equipment, has acquired two companies for a total of $11 million, the company announced Wednesday. The deals are expected to boost the company's electrophysiology business.

Fueled by an increase in stock-based compensation related to the company's spin-off from Harvard Bioscience last November, Holliston-based Harvard Apparatus Regenerative Technology, Inc. (HART) reported a net loss for the quarter of $3 million, or 39 cents per share; an increase from $2 million from for the same period in 2013.

Harvard Bioscience said winter weather dragged down first-quarter revenue slightly, as the life sciences manufacturer brought in $25.9 million, down 0.7 percent from $26.1 million in the first quarter of 2013.

Holliston-based medical device manufacturer Harvard Bioscience will cut about 13 percent of its workforce around the world as part of a reorganization that it said will position the company to grow.

KURT ISAACSON and BRAD GREENSTEIN were hired and KRISTIN NOLAN promoted by Spectrum Health Systems, based in...

Holliston-based Harvard Bioscience completed the spinoff of the regenerative medical device portion of its company last week, the company said.

Holliston-based Harvard Bioscience has spun off part of its business, which makes regenerative medical devices, the company announced.

Holliston-based Harvard Bioscience reported an 8.4-percent drop in revenue for its second quarter, as well as a net loss of $186,000. That marked a $962,000-turnaround after the life sciences manufacturer turned a $774,000 profit in the same quarter last year.